(RXRX) Recursion Pharmaceuticals - Ratings and Ratios
Drug,Candidates,Pipeline
RXRX EPS (Earnings per Share)
RXRX Revenue
Description: RXRX Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is a biotechnology company listed on the NASDAQ exchange. As a common stock, it represents ownership in the company. With a market capitalization of approximately $2.47 billion, Recursion Pharmaceuticals is considered a mid-cap stock in the biotechnology sub-industry.
The companys stock has exhibited volatility, with a 52-week high of $10.87 and a low of $3.97, indicating significant price fluctuations. The current price is around $5.41, with a beta of 0.924, suggesting that the stocks price movements are relatively correlated with the overall market.
From a fundamental analysis perspective, Recursion Pharmaceuticals has a negative Return on Equity (RoE) of -74.68%, indicating that the company is currently unprofitable. The absence of a Price-to-Earnings (P/E) ratio further reinforces this notion, as the company is likely operating at a loss. Key drivers of the companys stock performance may include research and development progress, clinical trial results, and industry trends.
To evaluate the companys potential, key performance indicators (KPIs) such as revenue growth, cash burn rate, and pipeline development progress should be closely monitored. Additionally, industry trends, competitive landscape, and regulatory developments will likely impact the companys stock performance. A thorough analysis of these factors is essential to making informed investment decisions.
From an economic perspective, the biotechnology industry is driven by factors such as innovation, research funding, and government policies. The demand for biotechnology products and services is influenced by the prevalence of diseases, aging population, and advances in medical technology. As Recursion Pharmaceuticals operates in this industry, its success will be tied to its ability to innovate, develop effective treatments, and navigate the complex regulatory environment.
RXRX Stock Overview
| Market Cap in USD | 2,052m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-04-16 |
RXRX Stock Ratings
| Growth Rating | -71.6% |
| Fundamental | 26.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -37.6% |
| Analyst Rating | 3.38 of 5 |
RXRX Dividends
Currently no dividends paidRXRX Growth Ratios
| Growth Correlation 3m | -33.5% |
| Growth Correlation 12m | -67.3% |
| Growth Correlation 5y | -69.5% |
| CAGR 5y | -23.72% |
| CAGR/Max DD 3y | -0.32 |
| CAGR/Mean DD 3y | -0.48 |
| Sharpe Ratio 12m | -0.99 |
| Alpha | -39.87 |
| Beta | 0.708 |
| Volatility | 77.45% |
| Current Volume | 17162.5k |
| Average Volume 20d | 15124.8k |
| Stop Loss | 4.5 (-6.8%) |
| Signal | -0.69 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-649.0m TTM) > 0 and > 6% of Revenue (6% = 3.87m TTM) |
| FCFTA -0.29 (>2.0%) and ΔFCFTA 10.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 656.6% (prev 886.7%; Δ -230.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.29 (>3.0%) and CFO -383.0m > Net Income -649.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.58 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (417.4m) change vs 12m ago 72.32% (target <= -2.0% for YES) |
| Gross Margin -3.76% (prev -26.05%; Δ 22.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 6.20% (prev 6.34%; Δ -0.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -301.4 (EBITDA TTM -583.5m / Interest Expense TTM 2.15m) >= 6 (WARN >= 3) |
Altman Z'' -11.40
| (A) 0.32 = (Total Current Assets 587.2m - Total Current Liabilities 164.0m) / Total Assets 1.30b |
| (B) -1.39 = Retained Earnings (Balance) -1.81b / Total Assets 1.30b |
| warn (B) unusual magnitude: -1.39 — check mapping/units |
| (C) -0.62 = EBIT TTM -646.8m / Avg Total Assets 1.04b |
| (D) -4.60 = Book Value of Equity -1.76b / Total Liabilities 383.2m |
| Total Rating: -11.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.17
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -23.75% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -0.08 = -2.50 |
| 6. ROIC - WACC -82.02% = -12.50 |
| 7. RoE -76.07% = -2.50 |
| 8. Rev. Trend 10.76% = 0.54 |
| 9. Rev. CAGR 14.85% = 1.86 |
| 10. EPS Trend -68.74% = -1.72 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of RXRX shares?
Over the past week, the price has changed by +4.77%, over one month by -10.72%, over three months by -6.58% and over the past year by -25.69%.
Is Recursion Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RXRX is around 3.68 USD . This means that RXRX is currently overvalued and has a potential downside of -23.81%.
Is RXRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RXRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 34% |
| Analysts Target Price | 6.5 | 34% |
| ValueRay Target Price | 4.1 | -15.1% |
Last update: 2025-09-03 04:46
RXRX Fundamental Data Overview
CCE Cash And Equivalents = 528.2m USD (Cash And Short Term Investments, last quarter)
P/S = 31.7633
P/B = 2.2323
Beta = 0.924
Revenue TTM = 64.4m USD
EBIT TTM = -646.8m USD
EBITDA TTM = -583.5m USD
Long Term Debt = 14.2m USD (from longTermDebt, last quarter)
Short Term Debt = 32.2m USD (from shortTermDebt, last quarter)
Debt = 46.4m USD (Calculated: Short Term 32.2m + Long Term 14.2m)
Net Debt = -440.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.57b USD (2.05b + Debt 46.4m - CCE 528.2m)
Interest Coverage Ratio = -301.4 (Ebit TTM -646.8m / Interest Expense TTM 2.15m)
FCF Yield = -23.75% (FCF TTM -372.9m / Enterprise Value 1.57b)
FCF Margin = -578.6% (FCF TTM -372.9m / Revenue TTM 64.4m)
Net Margin = -1007 % (Net Income TTM -649.0m / Revenue TTM 64.4m)
Gross Margin = -3.76% ((Revenue TTM 64.4m - Cost of Revenue TTM 66.9m) / Revenue TTM)
Tobins Q-Ratio = -0.89 (set to none) (Enterprise Value 1.57b / Book Value Of Equity -1.76b)
Interest Expense / Debt = 1.03% (Interest Expense 480.0k / Debt 46.4m)
Taxrate = 21.0% (US default)
NOPAT = -646.8m (EBIT -646.8m, no tax applied on loss)
Current Ratio = 3.58 (Total Current Assets 587.2m / Total Current Liabilities 164.0m)
Debt / Equity = 0.05 (Debt 46.4m / last Quarter total Stockholder Equity 919.1m)
Debt / EBITDA = -0.08 (Net Debt -440.1m / EBITDA -583.5m)
Debt / FCF = -0.12 (Debt 46.4m / FCF TTM -372.9m)
Total Stockholder Equity = 853.1m (last 4 quarters mean)
RoA = -49.83% (Net Income -649.0m, Total Assets 1.30b )
RoE = -76.07% (Net Income TTM -649.0m / Total Stockholder Equity 853.1m)
RoCE = -74.58% (Ebit -646.8m / (Equity 853.1m + L.T.Debt 14.2m))
RoIC = -73.57% (NOPAT -646.8m / Invested Capital 879.1m)
WACC = 8.45% (E(2.05b)/V(2.10b) * Re(8.62%)) + (D(46.4m)/V(2.10b) * Rd(1.03%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 8.31%
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -372.9m)
Revenue Correlation: 10.76 | Revenue CAGR: 14.85%
Rev Growth-of-Growth: 14.07
EPS Correlation: -68.74 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 7.71
Additional Sources for RXRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle